CAS 1029877-94-8|Trelagliptin succinate

Introduction：Basic information about CAS 1029877-94-8|Trelagliptin succinate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Trelagliptin succinate BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Synonyms

Common Name	Trelagliptin succinate
CAS Number	1029877-94-8	Molecular Weight	475.470
Density	/	Boiling Point	/
Molecular Formula	C₂₂H₂₆FN₅O₆	Melting Point	/
MSDS	/	Flash Point	/

Names

Name	2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioic acid
Synonym	More Synonyms

Trelagliptin succinate BiologicalActivity

Description	Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.
Related Catalog	Signaling Pathways >>Metabolic Enzyme/Protease >>Dipeptidyl PeptidaseResearch Areas >>Metabolic Disease
References	[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus [2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus [3]. Long-term Study of SYR-472 [4]. SYR-472 Open-label Study

Description

Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.

Related Catalog

Signaling Pathways >>Metabolic Enzyme/Protease >>Dipeptidyl PeptidaseResearch Areas >>Metabolic Disease

References

[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

[2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

[3]. Long-term Study of SYR-472

[4]. SYR-472 Open-label Study

Chemical & Physical Properties

Molecular Formula	C₂₂H₂₆FN₅O₆
Molecular Weight	475.470
Exact Mass	475.186707
PSA	171.65000
LogP	1.23468
InChIKey	OGCNTTUPLQTBJI-XFULWGLBSA-N
SMILES	Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2cc(F)ccc2C#N)c1=O.O=C(O)CCC(=O)O
Storage condition	-20℃

Safety Information

Hazard Codes	Xi

Synonyms

Trelagliptin (succinate)

Trelagliptin succinate [USAN]

Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluoro-, butanedioate (1:1)

SYR472 succinate

Zafatek

SYR 472

2-({[6-[(3R)-3-aminopipidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)- yl}methyl)-4-fluorobenzonitrile hydrogen butanedioate

Succinic acid - 2-({6-[(3R)-3-amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile (1:1)

SYR111472 Succinate

SYR-472

Recommended......